Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies (Q39428686)

11 September 2017

Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies (English)

1 reference

11 September 2017

0 references

1 reference

Giorgio Giaccone

15

1 reference

ORCID Public Data File 2021

Carlo Ferrarese

17

object named as

Carlo Ferrarese

1 reference

11 September 2017

Fabrizio Piazza

1

1 reference

11 September 2017

Steven M Greenberg

2

1 reference

11 September 2017

Mario Savoiardo

3

1 reference

11 September 2017

Margherita Gardinetti

4

1 reference

11 September 2017

Luisa Chiapparini

5

1 reference

11 September 2017

Irina Raicher

6

1 reference

11 September 2017

Ricardo Nitrini

7

1 reference

11 September 2017

Hideya Sakaguchi

8

1 reference

11 September 2017

Monica Brioschi

9

1 reference

11 September 2017

Giuseppe Billo

10

1 reference

11 September 2017

Antonio Colombo

11

1 reference

11 September 2017

Francesca Lanzani

12

1 reference

11 September 2017

Giuseppe Piscosquito

13

1 reference

11 September 2017

Maria Rita Carriero

14

1 reference

11 September 2017

Fabrizio Tagliavini

16

1 reference

11 September 2017

Jacopo C DiFrancesco

18

1 reference

11 September 2017

26 April 2013

1 reference

11 September 2017

1 reference

11 September 2017

73

1 reference

11 September 2017

4

1 reference

11 September 2017

449-458

1 reference

11 September 2017

1 reference

21 January 2018

1 reference

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

Clinical manifestations of cerebral amyloid angiopathy-related inflammation

21 January 2018

1 reference

21 January 2018

1 reference

Course of cerebral amyloid angiopathy-related inflammation.

21 January 2018

1 reference

Case 159: cerebral amyloid angiopathy-related inflammation

21 January 2018

1 reference

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

21 January 2018

1 reference

Cerebral amyloid angiopathy related inflammation: three case reports and a review.

21 January 2018

1 reference

Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature

21 January 2018

1 reference

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria

21 January 2018

1 reference

Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation.

21 January 2018

1 reference

Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease.

21 January 2018

1 reference

Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency.

21 January 2018

1 reference

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients.

21 January 2018

1 reference

Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects

21 January 2018

1 reference

Autoantibodies to amyloid-beta and Alzheimer's disease.

21 January 2018

1 reference

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

21 January 2018

1 reference

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy

21 January 2018

1 reference

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.23857

1 reference

11 September 2017

1 reference